美国Pulmonx
Pulmonx总部位于加州红木城和瑞士Peseux，专注于开发和营销用于呼吸疾病诊治的微创医疗器械和技术。
在美国，Zephyr® EBV是一种尚在研究中的器械。按美国法律仅限于研究用途。

Pulmonx, based in Neuchâtel, Switzerland and Redwood City, California, is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.

The company is currently engaged in the design, development and manufacture of products to deliver effective endoscopic lung volume reduction (ELVR) to patients with emphysema-induced hyperinflation. ELVR involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing secretions and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung to allow increased ventilation to healthier areas of the lung, thereby achieving the benefits of surgical lung volume reduction with far fewer risks and complications.

Pulmonx takes a unique approach to treating emphysema by providing an assessment tool to plan and optimize EBV treatment. The Chartis® Pulmonary Assessment System is composed of a balloon catheter and a simple, easy-to-use console which characterises airflow within lung regions. The goal is to understand the patient’s specific lung anatomy in order to plan for optimal treatment.

The company has CE mark for the Zephyr EBV and the Chartis System, and Pulmonx products are sold in Europe, Asia, and in other countries worldwide. The company does not yet market or sell its products in the United States.